340B Drug Pricing Program

Course Code: REL-CHC-0-DPB

Hours: 0.5

Type: Online Course

Content Expiration Date: 12/31/2029

Learning Objectives:
Recall how the 340B program works, its benefits and goals, the types of covered entities, and eligibility for the program.
Identify some challenges and controversies about the 340B program.

Outline:
Section 1: Introduction

About This Course

Learning Objectives

Section 2: Overview

Meet Angelica

Program Overview

Program Benefits and Goals

Defining Terms

Calculating Ceiling Price

Process Flow

Revisiting Angelica

Key Takeaways

Section 3: Eligibility

Types of Covered Entities 

Eligibility Requirements

Revisiting Angelica

Key Takeaways

Section 4: Challenges and Controversies

Profits Margins

Brand Name Biologics Versus Generics

Orphan Drug Exception

Legislative: Pharma Versus 340B

Revisiting Angelica

Key Takeaways

Section 5: Conclusion

Subject Matter Expert: Shalla Newton, MSN, RN, NE-BC

Shalla is a subject matter expert (SME)/writer for Relias. She completed her BSN and two undergraduate degrees with top honors from the University of Wisconsin-Madison. Shalla earned her dual MSN degrees from Johns Hopkins University with top honors. She also maintains her post-baccalaureate nurse educator certificate (NE-BC). Shalla’s tenure spans over 20 years of cross-functional leadership and direct clinical roles in healthcare, biopharma/biotech, government affairs, managed care/market access, nonprofit patient advocacy, and research. Her subject matter expertise is in rare, orphan, and complex diseases. Her sub-expertise is in immune-mediated diseases (rheumatology and immunology), genetics, neurology, hematology/oncology, several pediatric diseases, population/public health, and larger systemic healthcare affairs. Shalla is a published author with leading rare disease experts and a global speaker. She also sits on scientific, advocacy, and legislative advisory boards. She has led national advocacy and disease awareness campaigns, including speaking before congress, leading to the first-in-class rare disease biologic approval and investigative treatment protocols. 

Target Audience:
The target audience for this course is: General Staff; in the following settings: Community Health Settings.

Relias Learning will be transparent in disclosing if any commercial support, sponsorship or co-providership is present prior to the learner completing the course.

Relias Learning has a grievance policy in place to facilitate reports of dissatisfaction. Relias Learning will make every effort to resolve each grievance in a mutually satisfactory manner. In order to report a complaint or grievance please contact Relias Learning at support@reliaslearning.com.

Course Delivery Method and Format
Asynchronous Distance Learning with interactivity which includes quizzes with questions/answers, and posttests.